If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.80    -0.10 (-1.12%)
Bid:
8.60
Ask:
9.00
Spread: 0.40 (4.651%)
Market Cap: £57.67m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Director Share Purchase

12 May 2021 14:50

RNS Number : 4257Y
Kromek Group PLC
12 May 2021
 

12 May 2021

 

Kromek Group plc

("Kromek" or the "Group")

 

Director Share Purchase

 

Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announces that Rakesh Sharma, Non-Executive Chairman, has today purchased 63,152 ordinary shares of 1 pence each in the Group ("Ordinary Shares") at a price of 15.83 pence per Ordinary Share.

 

Following this purchase, Mr Sharma has an interest in 374,856 Ordinary Shares, representing 0.09% of the issued share capital of the Group. 

 

 

For further information, please contact:

 

Kromek Group plc

 

Arnab Basu, CEO

Paul Farquhar, CFO

 

+44 (0)1740 626 060

Cenkos Securities plc (Nominated Adviser and Broker)

 

Max Hartley/Camilla Hume (NOMAD)

Julian Morse (Sales)

 

+44 (0)20 7397 8900

Luther Pendragon (PR)

 

Harry Chathli/Claire Norbury

+44 (0)20 7618 9100

 

 

About Kromek Group plc

 

Kromek Group plc is a technology group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over 150 full-time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and https://twitter.com/kromekgroup.

 

The Group makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Rakesh Sharma

2

Reason for the notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Kromek Group plc

b)

LEI

213800VLHYXGHEX5VQ48

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

 

GB00BD7V5D43

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

15.83 pence

63,152

 

d)

Aggregated information

- Aggregated volume- Price

 

 N/A

e)

Date of the transaction

12 May 2021

f)

Place of the transaction

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEADSAFLNFEFA
Date   Source Headline
8th Dec 20207:00 amRNSContract extensions for D3S products
3rd Dec 20207:00 amRNSKromek launches the D5 RIID radiation detector
2nd Nov 20207:00 amRNSKromek wins new sector-leading global OEM customer
2nd Nov 20207:00 amRNSResult of AGM
29th Oct 20207:00 amRNSDirectorate Change
14th Oct 20207:00 amRNSKromek CZT technology to improve cancer surgery
9th Oct 20204:41 pmRNSSecond Price Monitoring Extn
9th Oct 20204:36 pmRNSPrice Monitoring Extension
8th Oct 20205:28 pmRNSHolding(s) in Company
8th Oct 20204:44 pmRNSNotice of AGM and Publication of Annual Report
8th Oct 202012:58 pmRNSDirector Share Purchase
8th Oct 20207:00 amRNSAppointment of Non-executive Director
7th Oct 202011:13 amRNSDirector Share Purchase
7th Oct 202011:00 amRNSPrice Monitoring Extension
7th Oct 20207:00 amRNSFinal Results
28th Sep 20203:00 pmRNSHolding(s) in Company
17th Sep 20201:53 pmRNSHolding(s) in Company
27th May 20207:00 amRNSKromek awarded new DARPA bio-surveillance contract
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20209:05 amRNSSecond Price Monitoring Extn
1st May 20209:00 amRNSPrice Monitoring Extension
1st May 20207:00 amRNSFull Year Trading Update and Response to COVID-19
27th Apr 202010:57 amRNSHolding(s) in Company
21st Apr 20207:00 amRNSKromek receives Queen’s Award
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSKromek to produce ventilators to fight COVID-19
20th Mar 202010:52 amRNSHolding(s) in Company
18th Feb 20204:15 pmRNSHolding(s) in Company
27th Jan 202012:42 pmRNSSite visit by International Trade Secretary
9th Jan 20204:55 pmRNSHolding(s) in Company
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20197:00 amRNSDirector Share Purchase
12th Dec 20197:00 amRNSDirector Share Purchases
11th Dec 20197:00 amRNSInterim Results
5th Dec 20197:00 amRNSNotice of Results
4th Dec 20195:25 pmRNSHolding(s) in Company
26th Sep 20191:14 pmRNSResult of AGM
24th Sep 20197:00 amRNSKromek awarded two contracts for D3S products
30th Aug 20191:50 pmRNSNotice of AGM and Publication of Annual Report
1st Jul 20197:00 amRNSNew contracts for D3S in UK, US and Europe
27th Jun 20197:00 amRNSFinal Results
7th May 20197:00 amRNSTrading Update
1st May 20197:00 amRNSSecurity screening contract order expansion
29th Mar 20194:51 pmRNSChange of Adviser
18th Mar 20195:50 pmRNSDirector Dealings Correction
28th Feb 20191:00 pmRNSHolding(s) in Company
28th Feb 20191:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.